People · Operator
Named in public records as an officer, director or promoter · active 2011–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cynapsus Therapeutics Inc. | — | Pharmaceuticals | Series B | $44.7M | $569.6M | 2013 |
| CerSci Therapeutics Inc. | — | Pharmaceuticals | Series A | $12.0M | $371.7M | 2019 |
| Melior Pharmaceuticals I, Inc. | — | Pharmaceuticals | Pre-Seed | $375K | $17.7M | 2011 |
Perry Molinoff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Perry Molinoff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Williams | 1 | 7 |
| David Hill | 1 | 6 |
| Robert Adelson | 1 | 5 |
| John D. Harkey, Jr. | 1 | 5 |
| David Genecov | 1 | 4 |
| Tamar D. Howson | 1 | 3 |
| Julia Levy | 1 | 3 |
| Nathan Bryson | 1 | 3 |
| Tyler Brous | 1 | 3 |
| Bobba Venkatadri | 1 | 2 |
| Michael Saporito | 1 | 2 |
| Andrew Reaume | 1 | 2 |
| Toby Moskovits | 1 | 2 |
| Anthony Giovinazzo | 1 | 2 |
| Ilan Oren | 1 | 2 |
| Brent Duncan | 1 | 2 |
| David Hitt II | 1 | 1 |
| Scott Dax | 1 | 1 |
| Lucas Rodriguez | 1 | 1 |
| Alan D. C. Ryley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.